Anti-CTL-associated antigen 4: are regulatory T cells a target?
Gabriel
Emmanuel M
EM
The Cancer Institute of New Jersey, Department of Surgery, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick, New Jersey 08901, USA.
Lattime
Edmund C
EC
D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D000938:Antigen-Presenting Cells / Q000378:metabolism; D015703:Antigens, CD / Q000737:chemistry / Q000276:immunology*; D000943:Antigens, Differentiation / Q000737:chemistry / Q000276:immunology*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D060908:CTLA-4 Antigen; D003602:Cytotoxicity, Immunologic; D000939:Epitopes / Q000737:chemistry; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007107:Immune System; D000074324:Ipilimumab; D008954:Models, Biological; D050378:T-Lymphocytes, Regulatory / Q000276:immunology*
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D000943:Antigens, Differentiation; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; D000939:Epitopes; D000074324:Ipilimumab